Literature DB >> 3171182

In vivo modulation of myelopoiesis by prostaglandin E2. IV. Prostaglandin E2 induction of myelopoietic inhibitory activity.

P S Gentile1, L M Pelus.   

Abstract

Conditioned medium (CM) prepared from bone marrow (BM) or spleen (SPL) cells from mice injected with PGE2 in doses ranging from 0.0001 to 10 micrograms was found to contain an activity inhibitory to the proliferation of granulocyte-monocyte progenitor cells (CFU-GM). This activity was found in medium conditioned for 24 to 48 h, but was not present in medium conditioned for longer time intervals. BM cells from PGE2-treated mice incubated over a concentration range of 0.1 to 1.0 x 10(6) cells/ml and SPL cells over a range of 1.0 to 10 x 10(6) cells/ml produced CM with equivalent degrees of inhibition for CFU-GM proliferation. Titration of this activity revealed a significant inhibitory effect still present at a 1/256 dilution. Inhibitory activity was similar whether or not CM was prepared in the presence or absence of FCS. Inhibition of CFU-GM development was approximately equal in the presence of either PWM SPL CM or L cell CM as sources of CSF activity. Morphologic analysis of CFU-GM revealed an equivalent inhibition of monocyte, monocyte-neutrophil, and neutrophil CFU-GM by the PGE2-stimulated inhibitory activity. Equivalent picogram amounts of PGE were measured in CM derived from BM or SPL cells from either control or PGE2-treated mice, indicating a low probability that injected PGE2 was carried over in the CM and contributed to CFU-GM inhibition. Protease digestion of BM or SPL cell CM from PGE2-treated mice revealed a loss of inhibitory activity after trypsin, chymotrypsin, pronase, and neuraminidase treatment. Inhibitory activity was also ablated by heat treatment at 56 degrees C for 30 min and 100 degrees C for 5 min. Acrylamide-agarose gel filtration of BM CM revealed an active inhibitory fraction in the Mr range of 5.5 to 8.0 kDa. The results of the present study suggest that one of the mechanisms by which PGE2 exerts its in vivo myelopoietic inhibitory action may be by stimulating the production of an inhibitory factor or factors from BM and SPL cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3171182

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Modulation of myelopoiesis by prostaglandin E2: demonstration of a novel mechanism of action in vivo.

Authors:  L M Pelus
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 2.  Pleiotropic effects of prostaglandin E2 in hematopoiesis; prostaglandin E2 and other eicosanoids regulate hematopoietic stem and progenitor cell function.

Authors:  Louis M Pelus; Jonathan Hoggatt
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-06-21       Impact factor: 3.072

3.  Murine myeloid progenitor responses to GM-CSF and eosinophil precursor responses to IL-5 represent distinct targets for downmodulation by prostaglandin E(2).

Authors:  M I Gaspar Elsas; D Joseph; L Lintomen; E S Maximiano; M Bodstein; P Xavier Elsas; B B Vargaftig
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 4.  Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking.

Authors:  J Hoggatt; L M Pelus
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

5.  Recovery from hematopoietic injury by modulating prostaglandin E(2) signaling post-irradiation.

Authors:  Jonathan Hoggatt; Pratibha Singh; Kayla N Stilger; P Artur Plett; Carol H Sampson; Hui Lin Chua; Christie M Orschell; Louis M Pelus
Journal:  Blood Cells Mol Dis       Date:  2012-11-30       Impact factor: 3.039

6.  Monocytes-macrophages that express α-smooth muscle actin preserve primitive hematopoietic cells in the bone marrow.

Authors:  Aya Ludin; Tomer Itkin; Shiri Gur-Cohen; Alexander Mildner; Elias Shezen; Karin Golan; Orit Kollet; Alexander Kalinkovich; Ziv Porat; Gabriele D'Uva; Amir Schajnovitz; Elena Voronov; David A Brenner; Ron N Apte; Steffen Jung; Tsvee Lapidot
Journal:  Nat Immunol       Date:  2012-09-16       Impact factor: 25.606

7.  cAMP analogues downregulate the expression of granulocyte macrophage colony-stimulating factor (GM-CSF) in human bone marrow stromal cells in vitro.

Authors:  G Bug; J Aman; C Huber; C Peschel; H G Derigs
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.